伏诺拉生预防长期非甾体抗炎药治疗期间溃疡复发:随机、兰索拉唑对照的非劣效性及单盲扩展研究
这项3期24周多中心随机双盲活性对照研究纳入642例长期接受非甾体抗炎药且有消化性溃疡复发风险的门诊患者,比较伏诺拉生10mg或20mg与兰索拉唑15mg每日一次预防溃疡复发的非劣效性;双盲期证实两种剂量伏诺拉生对兰索拉唑15mg均非劣效,24周内镜确诊复发率分别为3.3%、3.4%和5.5%,未发现显著安全性问题;随后≥28周单盲扩展研究显示伏诺拉生有效且耐受良好,安全性特征与兰索拉唑15mg相似。
要点
- 伏诺拉生10mg和20mg对兰索拉唑15mg预防NSAID相关溃疡复发均达到非劣效。
- 24周内镜确诊溃疡复发率:伏诺拉生10mg组3.3%、20mg组3.4%、兰索拉唑15mg组5.5%。
- 扩展研究显示伏诺拉生使用超过1年有效且耐受良好,安全性特征与兰索拉唑15mg相似。
核心结论
- 双盲期证实伏诺拉生10mg和20mg对兰索拉唑15mg在长期接受NSAID治疗的患者中非劣效。
- 扩展研究中伏诺拉生使用超过1年有效且耐受良好,安全性特征与兰索拉唑15mg相似。
研究设计与样本
- 3期、24周、多中心、随机、双盲、活性对照研究,随后为3期、≥28周、多中心、单盲、平行组扩展研究。
- 纳入642例长期接受NSAID治疗且有消化性溃疡复发风险的门诊患者。
- 患者接受伏诺拉生10mg或20mg或兰索拉唑15mg每日一次。
主要发现
- 24周内内镜确诊复发性消化性溃疡的比例:伏诺拉生10mg组3.3%、伏诺拉生20mg组3.4%、兰索拉唑15mg组5.5%。
- 伏诺拉生10mg对兰索拉唑15mg的百分比差异为-2.2%(95%CI -6.2%至1.8%,p<0.001),伏诺拉生20mg对兰索拉唑15mg为-2.1%(95%CI -6.1%至2.0%,p<0.001)。
- 未发现显著安全性问题。
关键数值与推荐
- 主要终点为24周内复发性消化性溃疡比例,采用Farrington and Manning检验,显著性水平2.5%,非劣效界值8.3%。
- 伏诺拉生10mg和20mg对兰索拉唑15mg的非劣效性均得到验证。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use. DESIGN: A phase 3, 24-week, multicenter, randomised, double-blind (DB), active-controlled study, followed by a phase 3, ≥28 week, multicenter, single-blind, parallel-group extension study (EXT) in outpatients (n=642) receiving long-term NSAID therapy who are at risk of PU recurrence. The patients received vonoprazan (10 mg or 20 mg) or lansoprazole 15 mg once daily. For DB, non-inferiority of the proportion of patients with recurrent PU within 24 weeks was analysed by Farrington and Manning test (significance level 2.5%, non-inferiority margin 8.3%; primary endpoint), recurrent PU within 12 weeks, bleeding and time-to-event of PU (secondary endpoint) and treatment-emergent adverse events (TEAEs). For EXT, TEAEs (primary endpoint), recurrent PU and safety (secondary) were assessed up to 104 weeks for patients in the extension study. RESULTS: The non-inferiority of vonoprazan 10 mg and 20 mg to lansoprazole 15 mg was verified (percentage difference -2.2%,95% CI -6.2% to 1.8%, p<0.001; -2.1%,95% CI -6.1% to 2.0%, p<0.001, respectively). The proportion of patients with endoscopically confirmed recurrent PU within 24 weeks was 3.3%, 3.4% and 5.5%, for vonoprazan 10 mg, 20 mg and lansoprazole 15 mg, respectively. No significant safety concerns were identified. CONCLUSION: The non-inferiority of vonoprazan (10 and 20 mg) was verified in patients receiving long-term NSAIDs in DB; it was effective and well tolerated in EXT for longer than 1 year, with a safety profile similar to lansoprazole (15 mg). TRIAL REGISTRATION NUMBERS: NCT01452750, NCT01456260; Results.
引用
- Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2017. PMID: 28988197. doi:10.1136/gutjnl-2017-314010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。